NORTH AMITYVILLE, N.Y., Sept. 24, 2018 /PRNewswire/ -- Topix Pharmaceuticals, Inc. announces the launch of Replenix Brightening Boost Pigment Correcting Cream, a non-hydroquinone brightening treatment that corrects visible discoloration for a brighter, more even and luminous complexion.
The natural skin brighteners and botanical tone enhancing ingredients combine in this drug-free formulation to exfoliate skin and minimize the appearance of dark spots. For all skin types, this correcting cream is developed to work as a lotion or as a treatment mask, with soothing moisturization to optimize results of hydroquinone and retinol therapies.
Key ingredients include:
- Arbutin - Natural skin brightener proven to condition skin and promote an even skin tone
- Botanical Extract Blend - Natural extracts rich in antioxidants help to tone and brighten while soothing and calming skin
- Hexylresorcinol - Helps correct the appearance of hyperpigmentation and brighten skin in combination with topical exfoliants,
- Hexanoyl dipeptide-3 – Exfoliating peptide helping to shed damaged and pigmented skin, to reveal a fresher, brighter complexion
With regular use, Replenix Brightening Boost Pigment Correcting Cream improves visible discoloration, skin health and hydration and helps to prevent future damage for enhanced complexion confidence – with or without makeup.
Replenix Brightening Boost Pigment Correcting Cream should be applied twice daily. In the morning, apply a thin layer before your moisturizer and sunscreen. At night, apply your retinoid or hydroquinone treatments as you normally would followed by a generous layer of the Replenix Brightening Boost Pigment Correcting Cream immediately after. For best results, leave on for 30-45 minutes and tissue off any excess.
About Topix Pharmaceuticals
For over 35 years, Topix Pharmaceuticals, Inc., a leader in Micro-Branded skin care innovations, has developed products using the highest quality, pharmaceutical grade ingredients, to provide patients with safe and effective results.
SOURCE Topix Pharmaceuticals, Inc.